Trial Profile
A Prospective Study to Assess Omalizumab Efficacy in Patients with Severe Asthma Without Allergenic Sensitization
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 30 Mar 2017 New trial record
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology